Pathophysiology of therapeutic and cognitive side-effects of Electroconvulsive Therapy (ECT).

Pathophysiology of therapeutic and cognitive side-effects of Electroconvulsive Therapy (ECT). - (Patho)physiological mechanisms of ECT

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON30867

Enrollment

Registered

2007-10-23

Start date

2007-10-01

Completion date

Unknown

Last updated

2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression depressive disorder

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Males and females above 18 years of age - Unipolar major depressive disorder with and without psychotic features, first and recurrent episode

Exclusion criteria

Exclusion criteria: - Presence of a current or past relevant somatic or neurological disorder - Comorbid diagnosis of bipolar depression, schizophrenia or substance dependence. - MRI-related exclusion criteria like claustrophobia, metal in body, pacemaker, pregnancy, etc. - ECT course within the past year - Use of antidepressants (according to good clinical practice, antidepressants have to be withdrawn before an ECT course, so this will not be a major issue).

Design outcomes

Primary

Measure	Time frame
- Mood (categorical DSM-IV diagnose, severity assessed with observer rated questionaire) - A detail neuropsychological examination (focus on memory and executive functioning). - Neuroimaging, i.e. functional connectivity (fMRI), structural connectivity (DTI), and amygdale reactivity (fMRI: Hariri paradigm) - Hypothalamic-pituitary-adrenal axis functioning (dexamethason suppression test) by nine cortisol measures in saliva.	—

Measure

Time frame

- Mood (categorical DSM-IV diagnose, severity assessed with observer rated questionaire) - A detail neuropsychological examination (focus on memory and executive functioning). - Neuroimaging, i.e. functional connectivity (fMRI), structural connectivity (DTI), and amygdale reactivity (fMRI: Hariri paradigm) - Hypothalamic-pituitary-adrenal axis functioning (dexamethason suppression test) by nine cortisol measures in saliva.

—

Secondary

Measure	Time frame
N.A.	—

Countries

Netherlands

Outcome results